نتائج البحث - "RESIDUAL PLATELET REACTIVITY"

العلاقة: https://www.aterotromboz.ru/jour/article/view/215/240Test; CAPRIE Steering Committee. A randomised, blinded, trial of dopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339. doi:10.1016/S0140-6736(96)09457-3.; Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopido-grel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502. doi:10.1056/NEJMoa010746.; Yusuf S., Mehta S.R., Zhao F., Gersh B.J., Commerford P.J., BLumenthaL M. et aL. Early and Late Effects of CLopidogreL in Patients With Acute Coronary Syndromes. Circulation. 2003;107(7):966 -972. doi:10.1161/01.CIR.0000051362.96946.15.; Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., MontaLescot G., Theroux P. et aL. Addition of CLopidogreL to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med. 2005;352(12):1179-1189. doi:10.1056/nejmoa050522.; COMMIT (CLOpidogreL and MetoproLoL in Myocardial Infarction Trial) collaborative group. Addition of cLopidogreL to aspirin in 45 852 patients with acute myocardial infarction: randomised pLacebo-controLLed Trial. Lancet. 2005;36 6(9497):1607-1621. doi:10.1016/s0140-6736(05)67660-x.; VaLgimigLi M., Bueno H., Byrne R.A., Collet J.-P., Costa F., Jeppsson A. et aL. ESC Scientific Document Group; 2017 ESC focused update on dual antipLateLet therapy in coronary artery disease deveLoped in coLLaboration with EACTS: The Task Force for duaL antipLateLet therapy in coronary artery disease of the European Society of CardioLogy (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260. doi:10.1093/eurheartj/ehx419.; Mehta S.R., Yusuf S., Peters R.J.G., Bertrand M., Lewis B.S., Natarajan M.K. et aL; CLopidogreL in UnstabLe angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with cLopidogreL and aspirin foLLowed byLong-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533. doi:10.1016/s0140-6736(01)05701-4.; Mehta S.R., Tanguay J.-F., EikeLboom J.W., EikeLboom J.W., JoLLy S.S., Joyner C.D. et aL. CURRENT-OASIS 7 triaL investigators. DoubLe-dose versus standard-dose cLopidogreL and high-dose versusLow-dose aspirin in individuaLs undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factoriaL triaL. Lancet. 2010;376(9748):1233-1243. doi:10.1016/S0140-6736(10)61088-4.; Ho P.M., Peterson E.D., Wang L., Magid D.J., Fihn S.D., Larsen G.C. et aL. Incidence of death and acute myocardiaL infarction associated with stopping cLopidogreL after acute coronary syndrome. JAMA. 2008;299(5):532-539. doi:10.1001/jama.299.5.532.; CharLot M., NieLsen L.H., Lindhardsen J., AhLehoff O., OLsen A.-M.S., Lock Hansen M. et aL. CLopidogreL discontinuation after myocardiaL infarction and risk of thrombosis: a nationwide cohort study. Eur Heart J. 2012;33(20):2527-2234. doi:10.1093/eurheartj/ehs202.; Boggon R., van Staa T.P., Timmis A., Hemingway H., Ray K.K., Begg A. et aL. CLopidogreL discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardiaL infarction - a hospitaL registry-primary careLinked cohort (MINAP-GPRD). Eur Heart J. 2011;32(19):2376-2386. doi:10.1093/eurheartj/ehr340.; Varenhorst C., Jensevik K., Jernberg T., Sundstrom A., HasvoLd P., HeLd C. et aL. Duration of duaL antipLateLet treatment with cLopidogreL and aspirin in patients with acute coronary syndrome. Eur Heart J. 2014;35(15):96 9 - 978. doi:10.1093/eurheartj/eht438.; Mehran R., Baber U., Steg P.G., Ariti C., Weisz G., WitzenbichLer B. et aL. Cessation of duaL antipLateLet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2-year resuLts from a prospective observationaL study. Lancet. 2013;382(9906):1714-1722. doi:10.1016/S0140-6736(13)61720-1.; Roffi M., Patrono C., CoLLet J.P., MueLLer C., VaLgimigLi M., Andreotti F. et aL. 2015 ESC GuideLines for the management of acute coronary syndromes in patients presenting without persistent ST-segment eLevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment eLevation of the European Society of CardioLogy (ESC). Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320.; Ibanez B., James S., AgewaLL S., Antunes M.J., BucciareLLi-Ducci C., Bueno H. et aL. 2017 ESC GuideLines for the Management of Acute MyocardiaL Infarction in Patients Presenting With ST-segment ELevation: The Task Force for the Management of Acute MyocardiaL Infarction in Patients Presenting With ST-segment ELevation of the European Society of CardioLogy (ESC). Eur Heart J. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393.; Wiviott S.D., BraunwaLd E., McCabe C.H., MontaLescot G., RuzyLLo W., GottLieb S. et aL. PrasugreL versus CLopidogreL in Patients with Acute Coronary Syndromes. N Engl J Med. 2007;357:2001-2015. doi:10.1056/NEJMoa0706482.; WaLLentin L., Becker R.C., Budaj A., Cannon C.P., EmanueLsson H., HeLd C. et aL. TicagreLor versus CLopidogreL in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361(11):1045-1057. doi:10.1056/NEJMoa0904327.; Dewilde W.J.M., Oirbans T., Verheugt F.W.A., Kelder J.S., De Smet B.J.G.L., Herrman J.-P. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-1115. doi:10.1016/S0140-6736(12)62177-1.; Cannon C.P., Bhatt D.L., Oldgren J., Lip G.Y.H., Ellis S.G., Kimura T. et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513-1524. doi:10.1056/NEJMoa1708454.; Gibson C.M., Mehran R., Bode C., Halperin J., Verheugt F.W., Wildgoose P. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423-2434. doi:10.1056/NEJMoa1611594.; Lopes R.D., Heizer G., Aronson R., Vora A.N., Massaro T., Mehran R. et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509-1524. doi:10.1056/NEJMoa1817083.; Vranckx P., Lewalter T., Valgimigli M., Tijssen J.G., Reimitz P.-E., Eckardt L. et al. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. Am Heart J. 2018;196:105-112. doi:10.1016/j.ahj.2017.10.009.; Lupercio F., Giancaterino S., Villablanca P.A., Han F., Hoffmayer K., Ho G. et al. P2Y12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis. Heart. 2020;106(8):575-583. doi:10.1136/heartjnl-2019-315963.; Mega J.L., Braunwald E., Wiviott S.D., Bassand J.P., Bhatt D.L., Bode C. et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366(1):9-19. doi:10.1056/NEJMoa1112277.; Gimbel M.E. Randomised comparison of clopidogrel versus ticagrelor or prasugrel in patients of 70 years or older with non-ST-elevation acute coronary syndrome - POPular AGE. European Society of Cardiology Congress, Paris, France, August 31, 2019. Available at: https://esc365.escardio.org/Congress/ESC-CONGRESS-2019/Late-Breaking-Science-in-Acute-Coronary-Syndromes-1/202103-randomised-comparison-of-clopidogrel-versus-ticagrelor-or-prasugrel-in-patients-of-70-years-or-older-with-non-st-elevation-acute-coronary-syndrome-popular-ageTest.; Angiolillo D.J., Rollini F., Storey R.F., Bhatt D.L., James S., Schneider D.J. et al. International Expert Consensus on Switching Platelet P2YE Receptor-Inhibiting Therapies. Circulation. 2017;136(20):1955-1975. doi:10.1161/CIRCULATIONAHA.117.031164.; Руда М.Я., Аверков О.В., Комаров А.Л., Панченко Е.П., Шахнович Р.М., Явелов И.С. О возможностях ослабления интенсивности антитромбоцитарной терапии у больных после острого коронарного синдрома. Резолюция совета экспертов Общества специалистов по неотложной кардиологии. Атеротромбоз. 2018;(1):67 -69. doi:10.21518/2307-1109-2018-1-67-69.; Cuisset T., Deharo P., Quilici J., Johnson T.W., Deffarges S., Bassez C. et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070-3078. doi:10.1093/eurheartj/ehx175.; Price M.J., Berger P.B., Teirstein P.S., Tanguay J.-F., Angiolillo D.J., Spriggs D.; Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. The GRAVITAS Randomized Trial. JAMA. 2011;305(11):1097-1105. doi:10.1001/jama.2011.290.; Trenk D., Stone G.W., Gawaz M., Kastrati A., Angiolillo D.J., Muller U. et al. A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol. 2012;59(24):2159-2164. doi:10.1016/j.jacc.2012.02.026.; Collet J.-P., Cuisset T., Range G., Cayla G., Elhadad S., Pouillot C. et al. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. N Engl J Med. 201;367(22):2100- 2109. doi:10.1056/NEJMoa1209979.; Cayla G., Cuisset T., Silvain J., Leclercq F., Manzo-Silberman S., Saint-Etienne et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint randomized controlled superiority trial. Lancet. 2016;388(10055):2015-2022. doi:10.1016/S0140-6736(16)31323-X.; Sibbing D., Aradi D., Jacobshagen C., Gross L., Trenk D., Geisler T. et al. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial. Thromb Haemost. 2017;117(1):188-195. doi:10.1160/TH16-07-0557.; Claassens D.M.F., Vos G.J.A., Bergmeijer T.O., Hermanides R.S., van 't Hof A.W.J, van der Harst P. et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med. 2019;381(17):1621-1631. doi:10.1056/NEJMoa1907096.; https://www.aterotromboz.ru/jour/article/view/215Test

الإتاحة: https://doi.org/10.21518/2307-1109-2020-1-72-81Test
https://doi.org/10.21518/2307-1109-2017-3Test
https://doi.org/10.1016/S0140-6736Test(96)09457-3
https://doi.org/10.1056/NEJMoa010746Test
https://doi.org/10.1161/01.CIR.0000051362.96946.15Test
https://doi.org/10.1056/nejmoa050522Test
https://doi.org/10.1016/s0140-6736Test(05)67660-x
https://doi.org/10.1093/eurheartj/ehx419Test
https://doi.org/10.1016/s0140-6736Test(01)05701-4
https://doi.org/10.1016/S0140-6736Test(10)61088-4

View record in BASE

7

دورية أكاديمية

vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease

المؤلفون: Ellen M. K. Warlo, Alf-Åge R. Pettersen, Harald Arnesen, Ingebjørg Seljeflot

المصدر: Thrombosis Journal, Vol 15, Iss 1, Pp 1-8 (2017)

مصطلحات موضوعية: ADAMTS13, Von Willebrand factor, Aspirin, Residual platelet reactivity, Cardiovascular disease, Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12959-017-0151-3Test; https://doaj.org/toc/1477-9560Test

الوصول الحر: https://doaj.org/article/60768e5f95f04de3b73eb0aebaa8dc99Test

View record in DOAJ

النص الكامل

8

دورية أكاديمية

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function

المؤلفون: Di Costanzo, Assunta, Indolfi, Ciro, Sorrentino, Sabato, Esposito, Giovanni, Spaccarotella, Carmen Anna Maria

المساهمون: Di Costanzo, Assunta, Indolfi, Ciro, Sorrentino, Sabato, Esposito, Giovanni, Spaccarotella, Carmen Anna Maria

مصطلحات موضوعية: LDL-C, PCSK9i, anticholesterolemic drug, ezetimibe, hypercholesterolemia, icosapent ethyl, inclisiran, platelet, residual platelet reactivity, statin, triglycerides

العلاقة: volume:24; issue:14; firstpage:11739; journal:INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; https://hdl.handle.net/11588/936270Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85165944471

الإتاحة: https://doi.org/10.3390/ijms241411739Test
https://hdl.handle.net/11588/936270Test

View record in BASE